Skip to main content
TipRanks
Go Ultimate75% OFF

StemCell Institute (7096) AI Stock Analysis

0 Followers
JP:7096

StemCell Institute

(TSE/TYO:7096)

Select Model
Rating:60Neutral
Price Target:JPY 672.00â–²(4.51% Upside)
Action:reiterated
Date:11/18/26

Financial performance is the primary driver, reflecting solid long-term growth offset by 2026 cash flow weakness. Bearish technical indicators add notable downward pressure, while high valuation multiples contribute further caution.

Positive Factors
Steady Revenue GrowthSustained revenue growth indicates continued demand and an expanding operating base, even as the pace moderates. Maintaining top-line expansion gives the company a foundation for rebuilding profitability and supports ongoing investment in its stem cell-related healthcare activities.
Negative Factors
Deteriorating Cash GenerationThe sharp decline in operating cash flow and deeply negative free cash flow reduce confidence that current operations can fund investment internally. Continued volatility could increase reliance on financing and constrain the company’s ability to pursue growth without added balance-sheet pressure.

StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)

-20%-10%0%10%20%30%40%JP:7096-15.84%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 6.43B
Dividend Yield
―
Average Volume (3M)
5,151
Price to Earnings (P/E)
57.3
Beta (1Y)
0.52
Revenue Growth
2.55%
EPS Growth
-43.06%
Country
Japan
Employees
117
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

StemCell Institute Business Overview & Revenue Model

Company Description

StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, an...

StemCell Institute Financial Statement Overview

Summary

Revenue growth and strong balance sheet with low debt provide stability, though recent declines in net margins and negative free cash flow highlight potential risks in 2026.

Income Statement

72Positive

Balance Sheet

85Very Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.81B2.81B2.68B2.48B2.09B1.78B
Gross Profit1.71B1.71B1.69B1.58B1.34B1.11B
EBITDA368.87M379.99M695.19M534.00M402.49M309.47M
Net Income153.86M155.92M385.80M310.98M198.03M133.73M
Balance Sheet
Total Assets8.12B8.12B7.52B6.59B5.83B5.23B
Cash, Cash Equivalents and Short-Term Investments2.83B2.83B3.20B2.85B3.32B3.51B
Total Debt473.81M473.81M518.96M10.78M5.89M0
Total Liabilities5.05B5.05B4.89B3.90B3.53B3.13B
Stockholders Equity2.68B2.68B2.63B2.69B2.30B2.10B
Cash Flow
Free Cash Flow0-335.78M-10.11M132.97M39.77M264.81M
Operating Cash Flow073.51M467.69M334.63M99.67M469.29M
Investing Cash Flow0-337.92M-259.08M-811.77M-285.10M404.17M
Financing Cash Flow0-175.09M146.70M-1.33M-869.00K644.37M

StemCell Institute Technical Analysis

Technical Analysis SentimentNegative
Last Price643.00

Price Trends

50DMA716.98Negative
100DMA729.88Negative
200DMA749.41Negative

Market Momentum

MACD-22.54Positive
RSI33.88Neutral
STOCH21.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 643.00 is below the 20-day moving average (MA) of 679.85, below the 50-day MA of 716.98, and below the 200-day MA of 749.41, indicating a bearish trend. The MACD of -22.54 indicates Positive momentum. The RSI at 33.88 is Neutral, neither overbought nor oversold. The STOCH value of 21.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.

StemCell Institute Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7096 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7096JP:709660NeutralJPY 6.59B57.28――2.55%-43.06%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497842NeutralJPY 11.33B-23.68――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 25.58B-69.38――17.05%10.47%
JP:4599JP:459938UnderperformJPY 7.90B-4.21―――4.85%
JP:4593JP:459337UnderperformJPY 27.92B-12.37――-51.55%52.19%
JP:7776JP:777637UnderperformJPY 6.11B-4.70――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:7096JP:4593JP:4599JP:4978JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7096 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7096StemCell Institute643.00-113.00-14.95%
JP:4593Healios KK206.00-280.00-57.61%
JP:4599StemRIM Inc.126.00-151.00-54.51%
JP:4978ReproCELL Inc.105.00-55.00-34.38%
JP:7774Japan Tissue Engineering Co., Ltd.630.00151.0031.52%
JP:7776CellSeed Inc.154.00-225.00-59.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026